Table 4.
The distribution of antiparkinsonian therapy used in the patients studied.
Therapies | Patients (n) | Percent (%) |
---|---|---|
Drug naïve | 12 | 8.89 |
Levodopa monotherapy | 50 | 37.04 |
DA monotherapy | 11 | 8.15 |
Levodopa + DA | 61 | 45.19 |
Others | 1 | 0.74 |
DA: dopamine agonists.